Wainua (eplontersen) Letter of Medical Necessity
Wainua (eplontersen) is a monthly self-injected TTR silencer for hereditary ATTR polyneuropathy. Payers approve it when genetics, neuropathy staging, and specialist involvement are documented, and deny it when any one is missing or when another TTR therapy is on the claim history. A Letter of Medical Necessity should address all three.
FDA-Approved Indications
- ● polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults
Why Wainua Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Pathogenic TTR variant not confirmed by genetic testing
- 2. Polyneuropathy stage or baseline neuropathy scores (FAP stage, PND, mNIS+7) not documented
- 3. Concurrent use with another TTR silencer or stabilizer not addressed
- 4. Prescriber is not a neurologist or amyloidosis specialist
- 5. Prior liver transplant or cardiomyopathy-only diagnosis outside the labeled indication
What to Include in a Wainua Letter of Medical Necessity
Attach the genetic test report confirming a pathogenic TTR variant, the polyneuropathy stage (FAP stage or PND score) with baseline mNIS+7 or NIS and Norfolk QoL-DN where available, and nerve conduction findings. State that no other TTR silencer will be used concurrently, document vitamin A supplementation, and explain why a self-administered monthly option is clinically preferred for this patient.
Key clinical evidence to cite:
- ✓ NEURO-TTRansform Phase 3 trial — significant reduction in serum TTR and improvement in mNIS+7 and Norfolk QoL-DN vs external placebo
- ✓ Monthly self-administered subcutaneous autoinjector, avoiding infusion visits
- ✓ Consensus that early TTR-lowering therapy slows neuropathy progression in hATTR
Relevant guidelines:
- 📖 European ATTR Amyloidosis Network Recommendations
- 📖 AAN Practice Guidance on hATTR Polyneuropathy
- 📖 ACC 2023 Expert Consensus on Cardiac Amyloidosis
Wainua Prior Authorization Criteria
Standard criteria across major US payers for Wainua. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Prior liver transplant or cardiomyopathy-only diagnosis outside the labeled indication
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Wainua
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Wainua Prior Authorization FAQ
Why was my Wainua prior authorization denied?
The most common denial reasons for Wainua are: Pathogenic TTR variant not confirmed by genetic testing; Polyneuropathy stage or baseline neuropathy scores (FAP stage, PND, mNIS+7) not documented; Concurrent use with another TTR silencer or stabilizer not addressed; Prescriber is not a neurologist or amyloidosis specialist; Prior liver transplant or cardiomyopathy-only diagnosis outside the labeled indication.
What should a Wainua Letter of Medical Necessity include?
Attach the genetic test report confirming a pathogenic TTR variant, the polyneuropathy stage (FAP stage or PND score) with baseline mNIS+7 or NIS and Norfolk QoL-DN where available, and nerve conduction findings. State that no other TTR silencer will be used concurrently, document vitamin A supplementation, and explain why a self-administered monthly option is clinically preferred for this patient.
Which payers cover Wainua?
Wainua is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.